Nilotinib Viatris (Nilotinib)

Nilotinib selectively blocks the BCR‑ABL tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome translocation. Inhibiting this kinase disrupts downstream signaling pathways that promote leukemic cell growth and survival, leading to reduced proliferation and increased programmed cell death of malignant cells.

The specific dose of Nilotinib Viatris is determined by the prescribing physician based on the patient’s disease stage, prior therapy, and individual health factors. Dosage adjustments may be required for renal or hepatic impairment, and the prescriber will provide detailed instructions tailored to each patient.

Safety data for nilotinib in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and selectivity compared with first‑generation agents like imatinib. Clinical studies show faster and deeper molecular responses in many patients, though safety profiles differ, with nilotinib associated with a higher incidence of cardiovascular events that require monitoring.

Nilotinib Viatris tablets should be stored at ambient temperature, below 25 °C. Keep the product in its original container, protect it from moisture, excessive heat, and direct sunlight. Do not refrigerate or freeze the tablets, as temperature extremes may affect stability.

Nilotinib Viatris is taken orally, usually as whole tablets with a moderate‑fat meal to enhance absorption. Patients should swallow the tablets whole with water and follow the dosing schedule prescribed by their healthcare provider, typically twice daily, unless otherwise directed.

The most serious risks include cardiovascular events such as arterial occlusion, QT interval prolongation leading to arrhythmias, severe hepatotoxicity, and pancreatitis. Patients should be monitored regularly for cardiac symptoms, liver function abnormalities, and electrolyte disturbances, and any concerning signs should prompt immediate medical evaluation.

Nilotinib is contraindicated in patients with known hypersensitivity to nilotinib or any of its excipients. It should also be avoided in individuals with uncontrolled cardiovascular disease, severe hepatic impairment, or those taking strong CYP3A4 inhibitors that cannot be discontinued. Clinical judgment is essential for each case.